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We investigated the relationship between preoperative comorbidity and postoperative survival after intestinal transplantation. Each
patient received a score for preoperative comorbidity. Each comorbidity was given a score based on the degree it impaired function
(score range 0–3). A total score was derived from the summation of individual comorbidity scores. Patients (72 adults (M : F, 33 : 39))
received an isolated intestinal graft (27) or a cluster graft (45). Mean (standard deviation) survival was 1501 (1444) days.TheKaplan-
Meier analysis revealed a significant inverse association between survival and comorbidity score (logrank test for trend,𝑃 < 0.0001).
Patients grouped into comorbidity scores of 0 and 1, 2 and 3, 4 and 5, 6, and above had hazard ratios (95% confidence intervals)
for death (compared to group 0 + 1), which increased with comorbidity scores: 1.945 (0.7622–5.816), 5.075 (3.314–36.17), and 13.77
(463.3–120100), respectively, (𝑃 < 0.0001). Receiver-operator curves at 1, 3, 5, and 10 years postoperative had “C” statistics of 0.88,
0.85, 0.88, and 0.92, respectively. When evaluating patients for transplantation, the degree of comorbidity should be considered as
a major factor influencing postoperative survival.
1. Introduction
Over the last decade, intestinal transplantation has become
an established treatment modality in the management of
intestinal failure.The preoperative status of patients has been
found to influence the outcome of surgery [1], and scores
developed to semiquantify this [2, 3] have been used in
routine practice to facilitate preoperative risk assessment.
There has been considerable improvement in postoperative
survival over the last 20 years. Much of this improvement
has arisen from advances in immunosuppressive regimes and
better preoperative preparation and postoperative care of
patients [4]. Although survival after transplantation remains
inferior to that on parenteral nutrition (PN), the gap is
closing, and as a consequence patients are being considered
for transplantation at an earlier stage. Potential improvement
in quality of life is also now being factored in to the decision
regarding a patient’s suitability for transplantation. It has
therefore become very important to accurately assess patient’s
individual survival chance. In our routine clinical practice,
we have considered preoperative comorbidity to have a
negative influence on postoperative survival [3]. We have
semiquantified comorbidity for each patient and compared
this to postoperative survival to determine the relationship.
2. Methods
Preoperative comorbidity was transformed into a numerical
score to allow service analysis to take place. This work was
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Table 1: Pretransplant risk assessment score for intestinal and
multivisceral transplantation in adults.The score was assigned to the
severity of each comorbidity resulting in a cumulative comorbidity
score.
Score Degree of comorbidity
0 Normal
1
Comorbidity with no significant functional impairment
requiring treatment: (mild hypertension, slight glucose
intolerance—diet controlled, mild exercise-induced
asthma, renal impairment—slightly impaired GFR
reduced by 10% only, smoker without respiratory
dysfunction, and past history of depressive illness)
2
Comorbidity requiring treatment to prevent functional
impairment—deemed to present a slightly increased
surgical risk: (treated hypertension, mild coronary
artery disease without symptoms, DM-oral
hypoglycemics, mild asthma—stable on intermittent
therapy, renal impairment—moderately reduced GFR
10–25%, smoker with mild respiratory dysfunction but
no symptomatic limitation, treated and resolved
depression).
3
Comorbidity that despite treatment causes functional
impairment and presents a moderate risk to surgery:
(poorly controlled hypertension, angina controlled by
Tx—minor vessel disease, DM—insulin dependent,
renal impairment—moderately reduced GFR 25–50%,
treated but unresolved depression, COPD with mild
symptoms requiring occasional treatment during
exacerbations)
Venous access: after loss of two major venous access points each additional
loss scores one point.
conducted according to the requirements of the institution.
The scorewas compared to subsequent survival. Comorbidity
factors included were loss of venous access and impairment
of organs or systems not corrected by transplantation. Each
factor was scored 0–3. A score of 3 indicated a functional
abnormality not fully corrected by treatment of a severity
approaching a contraindication for transplantation. A score
of 1 describes a characteristic which does not present an
immediate risk but which may develop into a risk factor in
the future. A score of 2 indicates an abnormality of function
which is corrected by ongoing treatment and conveys mod-
erate risk (Table 1).
Following the loss of 2 large venous access sites suitable
for parenteral nutrition and high flow infusions (i.e., internal
jugular, subclavian, and femoral vein), each subsequent loss
was given a score of 1.
3. Surgery
Patients were selected for transplantation according to the
conventional indications as previously published [5, 6]. In
summary, these were irreversible intestinal failure and inabil-
ity to continue parenteral nutrition, due to such conditions as
loss of venous access and parenteral nutrition-induced liver
disease. Other indications included the need for extensive
evisceration to remove desmoid tumors. Patients received an
Table 2: Donor demographics.
Variables Results
Mean age (yrs ± SD) 21.18 ± 11.27
Mean weight (kgs ± SD) 57.37 ± 18.61
CMVmismatch (%) 21.16%
Cold ischemic time (min) 434 ± 117.1
intestinal graft either in isolation or as part of a cluster of
abdominal organs including liver (multivisceral) or exclud-
ing liver (modified multivisceral transplant). All patients
received induction therapy with either Alemtuzumab (Cam-
path 1H), Daclizumab (Zenapax), or a few with glucocor-
ticosteroids. The surgical techniques and postoperative care
were in keeping with those previously described [5].
4. Data Collection
The data were collected prospectively during routine preop-
erative evaluation at the transplant centres at the University
of Cambridge, United Kingdom, and University of Miami,
United States of America, from 1997 to 2003.The analysis was
undertaken retrospectively. Patient data were consecutively
entered into a database as a routine at each institution
from which data were acquired for the analysis. Where
comorbidity data were incomplete, patients were excluded
from the analysis; this was undertaken without knowledge of
their subsequent survival.
5. Statistics
The primary outcome measured was median recipient sur-
vival with 95% confidence interval (CI) and was calculated
by Kaplan-Meier (KM) approach with comparison using
logrank test.The accuracy of the comorbidity score to predict
postoperative survival was tested by using Harrell’s C statistic
which estimates the proportion of accurate predictions. A
Harrell’s C index varies from 0.5 to 1 reflecting no discrim-
ination to perfect discrimination, respectively.
Student’s 𝑡-test for analysis of variance was used.
6. Results
Thedonor and patient demographics are detailed in (Tables 2
and 3, resp.). A total of 72 adults (M : F, 33 : 39) were included
in the study.
Patients received either an isolated intestinal graft (𝑛 =
27) or intestine in combination with other organs including
liver (multivisceral) (𝑛 = 27) or excluding liver (modified
multivisceral) (𝑛 = 18). In 31 patients, the large intestine
was also transplanted, and 6 received a kidney. Mean (SD)
survival of the group was 1501 (1444) days. No repeat
transplantations were included in the cohort.
The cause of intestinal failure in recipients was most
commonly short gut syndrome (33%), and the most frequent
procedure in this cohort was multivisceral transplantation
(intestine, liver, and additional organs) in 38%, followed by
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Table 3: Recipient demographics.
Variables Results
Mean age (yrs ± SD) 35.76 ± 10.63
Sex (M : F) 1 : 1.49
Race (%)
Caucasian 75.06%
Afro-Caribbean 14.42%
Hispanic 10.52%
Mean weight (kgs ± SD) 51.95 ± 13.92
Mean time on the waiting list (days ± SD) 68.95 ± 18.47
Pre-op place (hospital : home) 1 : 1.35
Pre-Tx albumin (g/dL ± SD) 3.268 ± 0.688
Thrombosed veins (mean ± SD) 1.495 ± 1.291
HLA mismatch (mean ± SD) 1.035 ± 1.076
Indication for transplant (%)
Short gut 33.33%
Motility disorders 16.67%
Neoplasms 18.05%
Mucosal defects 13.51%
Others 18.33%
Types of transplant (%)
Multivisceral (MVT) 38.37%
Modified MVT 24.65%
Intestine alone 36.98%
Warm ischemic time (minutes ± SD) 39.35 ± 12.07
Table 4: Peri- and postoperative data.
Variables Results
Induction agents (%)
Corticosteroids 13.90%
Daclizumab (Zenapax) 16.66%
Alemtuzumab (Campath) 69.44%
Number of rejection episodes (mean ± SD) 1.22 ± 1.34
Severity of rejection episodes per patient
(mean ± SD)
Mild 1.419 ± 0.662
Moderate 0.391 ± 0.718
Severe 0.318 ± 0.547
Rejection-free period (days) (mean ± SD) 357.63 ± 21.54
Posttransplant hospital stay (days) (mean ± SD) 60.69 ± 45.57
isolated intestine (37%), andmodifiedmultivisceral (intestine
and other organs excluding liver) 25% (Table 3).
Most patients received Alemtuzumab (Campath 1H)
induction immunosuppression, and the mean (SD) number
of rejection episodes per patient was 1.22 ± 1.34 (Table 4).
6.1. Kaplan-Meier Survival Analysis. Individual patient co-
morbidity scores and their postoperative survivals were
found to correlate inversely (𝑟
𝑠
−0.72; 𝑃 < 0.0001). The
Kaplan-Meier (KM) curve analysis of the cumulative recipi-
ent survival revealed a significant inverse association between
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Figure 1: Km survival curves were plotted for patients grouped
according to comorbidity score (dashed line: comorbidity 0 + 1;
continuous line: comorbidity 2 + 3; dotted line: comorbidity 4 + 5;
and dashed/dotted line: comorbidity >6). Logrank test for trend
indicated a significant increase in rate of death with comorbidity
score, and compared with comorbidity 0 + 1, the hazard ratios for
death were found to increase with comorbidity score, 1.94 (0.76–
5.82), 5.07 (3.31–36.17), and 13.77 (46.3–120100), respectively; the
difference became significantly greater than group 0 + 1 at group
4 + 5 (𝑃 < 0.0001).
patient survival and comorbidity score as evaluated by the
logrank test for trend (𝑃 < 0.0001) (Figure 1). For the pur-
poses of comparing survival chance, patients were grouped
into comorbidity scores of 0 and 1, 2 and 3, 4 and 5, 6, and
above. The hazard ratio (95% CI) for death (compared to
group 0 + 1) was found to increase as the comorbidity score
increased: 1.945 (0.7622–5.816), 5.075 (3.314–36.17), and 13.77
(463.3-120100), respectively; this became significantly greater
than group 0 + 1 at group 4 + 5 (𝑃 < 0.0001) (Figure 1).
The survival of patients receiving isolated intestinal grafts
was compared to those who underwent multivisceral trans-
plantation. Kaplan-Meier analysis revealed no difference in
survival between patients receiving isolated andmultivisceral
transplantation: logrank (Mantel-Cox) test: 𝑃 = 0.43; hazard
ratio: 0.8129 (0.4599 to 1.366). Median survival for isolated
transplants (2007 days) was similar to that for multivisceral
grafts (3107 days).
6.2. Receiver-Operator Curve Analysis. The accuracy of the
score to predict postoperative survival was evaluated using
the receiver-operator characteristic analysis. A receiver-
operator curve (ROC curve) was constructed for survival
prediction at 1, 3, 5, and 10 years. The Harrell’s C statistic
was calculated for each curve and represents the overall
accuracy when assessed in terms of specificity and sensitivity
at all possible points. The C statistic indicated very good or
excellent accuracy of the comorbidity score at all times frames
(Figure 2, Table 5).
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Table 5
Receiver-operator curve (ROC) analysis for predicting death at postoperative time intervals.
Time point
assessed
Area under ROC curve
(Harrel’s “C” statistic)
Standard
error
95% confidence
interval
Significance
(P value)
Number of control
subjects
Number of
patients
1 yr 0.88 0.049 0.788–0.981 <0.0001 34 20
3 yrs 0.85 0.054 0.742–0.954 <0.0001 28 28
5 yrs 0.88 0.057 0.7761–0.9905 <0.0001 13 29
10 yrs 0.92 0.040 0.8454–1.003 <0.0001 10‘ 33
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Figure 2: Receiver-operator curves were calculated to assess accu-
racy of survival prediction at 1, 3, 5, and 10 years postoperative
(continuous line, dashed line, dashed/dotted line, and dotted line,
resp.). The accuracy of the comorbidity score is indicated by the
area under the curve (Harrell’s “C” statistic) and was very good
or excellent for predictions at each time frame with associated “C”
statistics of 0.88, 0.85, 0.88, and 0.92, respectively.
7. Discussion
We recognise that the interpretation of these data should
be undertaken in the context that there will be differences
in the protocols of transplant centres which might have
an influence on the relative importance of comorbidity on
survival. For instance, the majority of patients in our cohort
received Alemtuzumab as induction therapy which may have
made the impact of comorbidity more significant. There
will also be additional influences on survival, particularly
in the long term, that are not included in this analysis.
Nevertheless, in this cohort of patients, our results indicate
that the degree of preoperative comorbidity appears to
predict posttransplant survival following small intestinal and
multivisceral transplantation in adults. The predictive value
of the comorbidity score might allow better patient selection,
focus on pretransplant optimization, and facilitate informed
consent for the procedure. Patients who have a low comor-
bidity score might be considered for earlier transplantation
or even preemptive transplantation, where transplantation
is offered at the time of developing intestinal failure. This
would be particularly appropriate for those with high risk
circumstances, where they are likely to have a reduced
life expectancy on PN [6], such as pseudoobstruction and
systemic sclerosis and possibly ultrashort bowel syndrome
(<30 cm of jejunum), rather than waiting for them to develop
the traditional indications through complications of their PN.
In better performing centres, it might be reasonable to offer
patients preemptive transplantation on the basis of improving
a very poor quality of life (QOL). Patients in comorbidity
groups 0 + 1 have a 10-year survival similar or better than
unselected patients on PN. However, before this becomes
common practice, it will be important to develop methods of
determiningwhich patientswill benefit in terms ofQOL from
transplantation, as it is clear that certain aspects of patient’s
lives do not improve with transplantation [7]. Furthermore,
the timing of transplantation might be influenced by the
desire to limit comorbidity to keep the comorbidity score
low. For instance, a patient with early comorbidity in several
body systemsmight benefit from early transplantation before
these deteriorate; conversely, patientswith active comorbidity
might have a better survival chance if transplantation is
delayed until they receive treatment to stabilise concurrent
illness.
As postoperative survival improves poor quality of life,
it is likely to become a more frequent indication for trans-
plantation. Under these circumstances, it will be crucial to
predict postoperative survival for individual patients to better
evaluate the risk/benefit ratio of transplantation and facilitate
informed consent, and the comorbidity scoremight also be of
considerable use for this purpose. As the role of other factors,
such as the presence of HLA antibodies, becomes clearer, this
scoring system may be improved by their inclusion [8].
In conclusion, the numeric score (comorbidity score)
developed to allow us to semiquantify preoperative comor-
bidity appears to be an accurate and convenient method
of assessing risk using preoperative risk factors. A future
multicentre international prospective study to evaluate this
survival risk factor is important to confirm our initial obser-
vation and may lead to a useful clinical tool in the selection
and timing of patients for transplantation.
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